Gland Pharma Limited has undergone substantial transformation since its establishment as a contract manufacturer specializing in small volume liquid parenteral formulations, evolving into one of the most prominent and rapidly expanding enterprises in the injectable pharmaceuticals sector. Operating across 60 nations, encompassing the United States, Europe, Canada, Australia, and India, the organization predominantly functions through a business-to-business (B2B) framework and maintains an exemplary portfolio in the research, production, and commercialization of sophisticated injectable formulations. The organization is presently conducting a Mega Apprentice Walk-In Interview targeting the Production Department, with recruitment focused on candidates possessing qualifications including ITI, Diploma, or B.Sc in Chemistry, ideally from the 2023-2025 graduating cohorts. Prospective applicants must be recent graduates with no previous employment history and must not be registered under ESIC or EPF schemes. The recruitment event is scheduled for October 17, 2026, between 9:30 AM and 11:30 AM at the Gland Pharma Ltd. facility situated in proximity to Hyderabad.
Vacancy details
Department: Production
Qualification: ITI, Diploma, B.Sc (Chemistry)
Passed out: Graduates from 2023-2025 batches are preferable
Experience: Freshers
Eligibility:
- Freshers without any work experience
- Not enrolled under ESIC & EPF
Documents Required
- Updated resume
- All Educational Certificates (Provisionals)
- Aadhar & Pan Card Xerox Copies
- Bank Account Details
- Photo with Signature
Walk-in Interview Details
Date of interview: 17th October 2026
Time: 09:30 AM-11:30 AM
Venue: Gland Pharma Limited, Survey No. 143-148, 150 & 151, near Gandi Maisamma X roads, D.P. Pally, Gandi Maisamma, Dundigal, Hyderabad, Telangana 500043.
About Gland Pharma Limited
Gland Pharma, founded in Hyderabad, India in 1978, has evolved from a contract manufacturer of small volume liquid parenteral products into one of the largest and fastest-growing companies in the generic injectables sector, boasting a presence in 60 countries, including the United States, Europe, Canada, Australia, and India. Operating primarily on a business-to-business (B2B) model, the company has established a strong reputation in pharmaceutical research and development, as well as in the manufacturing and marketing of complex injectables. This comprehensive engagement across the value chain has facilitated significant growth. The company is supported by a professional management team, with one of its promoters, Shanghai Fosun Pharma, being a prominent player in the global pharmaceutical industry.